Opinion
Video
Factors Impacting Use of HER2 Therapies for NSCLC
Key Takeaways
- Barriers to HER2-directed therapies include high costs, limited insurance coverage, and stringent prior authorization requirements, impacting patient access and treatment initiation.
- Providers prioritize clinical outcomes like progression-free survival and overall response rates, which may not align with payer focus on cost-effectiveness.
Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.
Video content above is prompted by the following:
Analyze payer perspectives and access challenges related to HER2-directed therapies in NSCLC.
- (Kim) What are potential barriers to starting and/or persisting on HER2-directed therapies for NSCLC?
- (Bazhenova) Which outcomes do providers find most important in clinical practice, and how do these align with the outcomes payers prioritize when assessing the value of these therapies?
Related Content
December 19th 2024
